2026
September
Breaking down the mechanism of enfortumab vedotin
September 9, 2026
Enfortumab vedotin (marketed under the brand name Padcev) is an approved antibody–drug conjugate (ADC) that targets Nectin-4 on cancer cells and delivers a payload of microtubule-disrupting monomethyl auristatin E (MMAE) to tumor cells. In recent work, Olson and Liu et al. thoroughly investigated the mechanism of action of enfortumab vedotin, and identified direct...
Aire-ing out a tumor’s dirty laundry: manipulating tumoral AIRE to boost antitumor immunity
September 2, 2026
The autoimmune regulator (AIRE) transcription factor in medullary thymic epithelial cells (mTECs) is essential for the negative selection of autoreactive T cells in the thymus by inducing expression of peripheral tissue-specific antigens. Chen, Pulido, et al. hypothesized that AIRE expression in cancer cells may mimic this thymic process by establishing a “selfness” profile...
